We found that 48 (66.7%) of the 72 patients with gastric cancer were negative for the pepsinogen test, while the serum TFF3 test identified an additional 30, the sensitivity of combining the results of serum TFF3 and pepsinogen tests was 75%, which was better than that of either tests alone. This evidence concerns the gene TFF3 and gastric cancer.